Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC

Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC is a phase 2, interventional study registered as NCT07291401 by Zhongnan Hospital, with a registry enrolment figure of 108 participants, started 2025-11-01 and due to reach its primary completion in 2027-01-01. Interventions recorded: lparomlimab and Tuvonralimab Injection and CPAOX and radiotherapy. Conditions listed: Rectal Cancer Patients. Primary outcome: Complete response (CR). Colorectal eligibility wording from the registry: "* (1) The patient is histologically diagnosed with rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.